Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: A randomized phase II study from the Nordic Lymphoma Group
The purpose of this phase II randomized trial was to evaluate the effect and safety of interferon-2a (IFN) in combination with extended dosing rituximab in patients with symptomatic, advanced indolent lymphoma responding to a standard single course of rituximab. Totally 123 patients were treated with rituximab 375mg/m2 once weekly for 4 weeks leading to 14 complete response (CR; 11%), 56 partial r
